Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acalabrutinib Real World Italian obSErvational Secondary Data Collection Study of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia.

NCT06205498 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06205498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06205498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acalabrutinib Real World Italian obSErvational Secondary Data Collection Study of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
August 8, 2023
Completion date
April 30, 2027
Enrollment
151 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia